Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX HELSINKI LTD.  >  Orion Oyj    ORNBV   FI0009014377

ORION OYJ

(ORNBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Orion upgrades full-year outlook for 2020

10/19/2020 | 01:35pm EST

ORION CORPORATION STOCK EXCHANGE RELEASE INSIDE INFORMATION 19 OCTOBER 2020 at 20.35 EEST             
         

Orion upgrades full-year outlook for 2020

Orion Corporation upgrades the full-year outlook for 2020, provided on 8 July 2020, both for the part regarding net sales and operating profit. In 2020, the net sales are estimated to be at a similar level as in 2019 or slightly higher than in 2019. Operating profit is estimated to be higher or clearly higher than in 2019.

In January–September 2020 Orion’s preliminary net sales were EUR 823 million and preliminary operating profit was EUR 246 million.

Due to the COVID-19 pandemic the whole year international sales of Dexdor® will be clearly higher than expected at the start of the year. The demand spike of generic prescription drugs and self-care products in March has levelled off during the year as expected but the full-year sales of some products, however, will be higher than expected at the start of the year. Additionally, the risk of COVID-19-induced lower product availability in 2020 has reduced significantly. Due to these reasons, among others, Orion estimates the full-year 2020 net sales to be at a similar level as in 2019 or slightly higher than in 2019.

Mainly due to the COVID-19 pandemic the full-year operating expenses of Orion will be lower than estimated earlier. Due to the net sales that will be higher than estimated at the start of the year, favourable sales margin structure of the sold products and lower than estimated earlier operating expenses Orion estimates the full-year 2020 operatig profit to be higher or clearly higher than in 2019.

The new outlook is based on the assumption that Orion‘s own production can continue normal operations despite the COVID-19 pandemic also during the remainder of the year. This requires that Orion continues to succeed in protecting its employees and employee absence rates do not significantly increase, that personal protective equipment, starting materials, intermediate products and materials are available and that the logistics chains are sufficiently functional.

New full-year outlook, provided on 19 October 2020

Orion estimates that in 2020 net sales will be at a similar level as in 2019 or slightly higher than in 2019 (net sales in 2019 were EUR 1,051 million).

Operating profit is estimated to be higher or clearly higher than in 2019 (in 2019 operating profit was EUR 253 million).

Previous full-year outlook, provided on 8 July 2020

Orion estimates that in 2020 net sales will be at a similar level as in 2019 (net sales in 2019 were EUR 1,051 million).

Operating profit is estimated to be slightly higher or higher than in 2019 (in 2019 operating profit was EUR 253 million).

Orion publishes Interim Report for January–September 2020 on Wednesday 21 October 2020.

Orion Corporation

Timo Lappalainen
President and CEO
   Olli Huotari
SVP, Corporate Functions
 

                                                                                                                                   
Contact persons:

Jari Karlson, CFO
tel. +358 10 426 2883 

Tuukka Hirvonen, Investor Relations
tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

 

Primary Logo


© GlobeNewswire 2020
All news about ORION OYJ
01/12ORION OYJ : Recommendation by the Nomination Committee concerning the Board of D..
AQ
2020NUVO PHARMACEUTICALS INC : . - Miravo Healthcare Ireland Enters into Suvexx Lice..
AQ
2020ORION OYJ : 8,242 Orion Corporation A shares converted into B shares
AQ
2020ORION OYJ : invests EUR 17 million in its production plants in Turku
PU
2020ORION OYJ : Prosecutor pressed charges against a member of Orion's Board of Dire..
PU
2020ORION OYJ : Prosecutor pressed charges against a member of Orion's Board of Dire..
AQ
2020Prosecutor pressed charges against a member of Orion's Board of Directors for..
GL
2020ORION OYJ : Composition of the Nomination Committee of Orion Corporation
PU
2020ORION OYJ : Composition of the Nomination Committee of Orion Corporation
AQ
2020Composition of the Nomination Committee of Orion Corporation
GL
More news
Financials
Sales 2020 1 090 M 1 317 M 1 317 M
Net income 2020 236 M 285 M 285 M
Net cash 2020 134 M 162 M 162 M
P/E ratio 2020 23,4x
Yield 2020 3,79%
Capitalization 5 497 M 6 647 M 6 642 M
EV / Sales 2020 4,92x
EV / Sales 2021 5,03x
Nbr of Employees 3 320
Free-Float 86,5%
Chart ORION OYJ
Duration : Period :
Orion Oyj Technical Analysis Chart | ORNBV | FI0009014377 | MarketScreener
Technical analysis trends ORION OYJ
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 32,95 €
Last Close Price 39,15 €
Spread / Highest target 7,28%
Spread / Average Target -15,8%
Spread / Lowest Target -28,5%
EPS Revisions
Managers and Directors
NameTitle
Timo Antero Lappalainen President & Chief Executive Officer
Satu Maarit Ahomäki Senior Vice President-Commercial Operations
Jari Ilmari Karlson Chief Financial Officer & SVP-Animal Health
Sinikka Markkula Chief Information Officer
Minna Ruotsalainen Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ORION OYJ4.32%6 647
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993